Responding to the

In September 2024, Zhejiang Jingyue Biotechnology Co., Ltd. was officially inaugurated in Ningbo. With the core philosophy of "Health as the Foundation, Quality as the Priority," the company has precisely positioned itself in the medicine and food homologous health food track, actively responding to the in-depth advancement of the national "Healthy China" strategy. Currently, China's big health industry is embracing a trillion-dollar blue-chip market, while the demand for national health is also showing a diversified and upgraded trend. Issues such as hyperuricemia, known as the "Four Highs," are becoming increasingly prominent, with nearly 170 million patients facing the dilemma of side effects from traditional solutions and limited efficacy of common health products.

Jingyue Bio emerged at this historic moment, integrating cutting-edge biotechnology with high-quality natural raw material resources to build a diversified big health platform covering the entire value chain of R&D, production, and sales of health foods. From its inception, the company has focused on strategic cooperation with the research team led by Professor Zhang Zhaotao from the School of Public Health at Wuhan University, leveraging the university's over a decade of technical accumulation in the field of bioactive ingredient research to focus on the core needs of chronic disease prevention and sub-health conditioning.

This collaboration will deeply integrate traditional health preservation philosophy with modern biotechnology, aiming to address the market pain points of "safety, efficacy, and multi-effect integration" in current health products, injecting new impetus into the improvement of national health. In the future, Jingyue Bio will, as a pioneer, continue to deepen its presence in the big health sector, bringing the healing power of nature to more consumers.